Quince Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	17.7	26.01	29.52	17.59	8.95	2.03	1.27
Research & Development	9.45	25.18	60.8	61.31	30.21	10.09	9.1
Other Operating Expenses	5.9	0.83	0	0	0	0	0
Operating Expenses	33.04	52.02	90.32	78.89	39.17	12.12	10.37
Operating Income	-33.04	-52.02	-90.32	-78.89	-39.17	-12.12	-10.37
Interest Expense / Income	0	0	0	0	0	0.96	1.64
Other Expense / Income	-1.46	-0.07	-0.37	-2.04	-2.19	-0.6	0.22
Pretax Income	-31.58	-51.94	-89.95	-76.85	-36.98	-12.48	-12.24
Income Tax	-0.2	-0.28	0	0	0	0	0
Net Income	-31.39	-51.66	-89.95	-76.85	-36.98	-12.48	-12.24
Shares Outstanding (Basic)	37	33	30	29	19	3	3
Shares Outstanding (Diluted)	37	33	30	29	19	3	3
Shares Change	11.17%	12.71%	1.86%	53.30%	466.06%	1.79%	-
EPS (Basic)	-0.84	-1.54	-3.03	-2.63	-1.94	-3.71	-3.70
EPS (Diluted)	-0.84	-1.54	-3.03	-2.63	-1.94	-3.71	-3.70
Free Cash Flow	-18.36	-44.1	-63.11	-50.87	-33.33	-11.91	-9.9
Free Cash Flow Per Share	-0.49	-1.32	-2.12	-1.74	-1.75	-3.54	-3.00
EBITDA	-31.26	-51.74	-89.6	-76.52	-36.79	-11.47	-10.55
Depreciation & Amortization	0.32	0.2	0.34	0.33	0.19	0.05	0.05
EBIT	-31.58	-51.94	-89.95	-76.85	-36.98	-11.52	-10.59

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).